Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2015

01-06-2015 | Original Article

Brain 18F-DOPA PET and cognition in de novo Parkinson’s disease

Authors: Agnese Picco, Silvia Morbelli, Arnoldo Piccardo, Dario Arnaldi, Nicola Girtler, Andrea Brugnolo, Irene Bossert, Lucio Marinelli, Antonio Castaldi, Fabrizio De Carli, Claudio Campus, Giovanni Abbruzzese, Flavio Nobili

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2015

Login to get access

Abstract

Purpose

The role of mesocortical dopaminergic pathways in the cognitive function of patients with early Parkinson’s disease (PD) needs to be further clarified.

Methods

The study groups comprised 15 drug-naive patients with de novo PD and 10 patients with essential tremor (controls) who underwent 18F-DOPA PET (static acquisition, normalization on mean cerebellar counts) and an extended neuropsychological test battery. Factor analysis with varimax rotation was applied to the neuropsychological test scores, to yield five factors from 16 original scores, which explained 82 % of the total variance. Correlations between cognitive factors and 18F-DOPA uptake were assessed with SPM8, taking age and gender as nuisance variables.

Results

18F-DOPA uptake was significantly lower in PD patients than in controls in the bilateral striatum, mainly in the more affected (right) hemisphere, and in a small right temporal region. Significant positive correlations were found only in PD patients between the executive factor and 18F-DOPA uptake in the bilateral anterior cingulate cortex (ACC) and the middle frontal gyrus, between the verbal fluency factor and 18F-DOPA uptake in left BA 46 and the bilateral striatum, and between the visuospatial factor and 18F-DOPA uptake in the left ACC and bilateral striatum. No correlations were found between 18F-DOPA uptake and either the verbal memory factor or the abstraction–working memory factor.

Conclusion

These data clarify the role of the mesocortical dopaminergic pathways in cognitive function in early PD, highlighting the medial frontal lobe, anterior cingulate, and left BA 46 as the main sites of cortical correlation with executive and language functions.
Appendix
Available only for authorised users
Literature
1.
Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol. 2010;9:1200–13.CrossRefPubMed
2.
Claassen DO, Wylie SA. Trends and issues in characterizing early cognitive changes in Parkinson’s disease. Curr Neurol Neurosci Rep. 2012;12:695–702.CrossRefPubMedCentralPubMed
3.
Arnaldi D, Campus C, Ferrara M, et al. What predicts cognitive decline in de novo Parkinson’s disease? Neurobiol Aging. 2012;33:1127.e11–20.CrossRef
4.
Olde Dubbelink KT, Hillebrand A, Twisk JW, et al. Predicting dementia in Parkinson disease by combining neurophysiologic and cognitive markers. Neurology. 2014;82:263–70.CrossRefPubMed
5.
Barone P. Neurotransmission in Parkinson’s disease: beyond dopamine. Eur J Neurol. 2010;17:364–76.CrossRefPubMed
6.
Brooks DJ, Pavese N. Imaging biomarkers in Parkinson’s disease. Prog Neurobiol. 2011;95:614–28.CrossRefPubMed
7.
Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegener Dis. 2013;11:79–92.CrossRefPubMed
8.
Marié RM, Barré L, Dupuy B, et al. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson’s disease. Neurosci Lett. 1999;260:77–80.CrossRefPubMed
9.
Rinne JO, Portin R, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol. 2000;57:470–5.CrossRefPubMed
10.
Brück A, Portin R, Lindell A, et al. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson’s disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett. 2001;311:81–4.CrossRefPubMed
11.
Cropley VL, Fujita M, Innis RB, et al. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry. 2006;59:898–907.CrossRefPubMed
12.
van Beilen M, Leenders KL. Putamen FDOPA uptake and its relationship to cognitive functioning in PD. J Neurol Sci. 2006;248:68–71.CrossRefPubMed
13.
Jokinen P, Brück A, Aalto S, et al. Impaired cognitive performance in Parkinson’s disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord. 2009;15:88–93.CrossRefPubMed
14.
Nobili F, Campus C, Arnaldi D, et al. Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson’s disease patients: a [I-123]FP-CIT SPECT study. Mov Disord. 2010;25:35–43.CrossRefPubMed
15.
Jokinen P, Karrasch M, Brück A, et al. Cognitive slowing in Parkinson’s disease is related to frontostriatal dopaminergic dysfunction. J Neurol Sci. 2013;329:23–8.CrossRefPubMed
16.
Holthoff VA, Vieregge P, Kessler J, et al. Discordant twins with Parkinson’s disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. 1994;36:176–82.CrossRefPubMed
17.
Calvini P, Rodriguez G, Inguglia F, et al. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging. 2007;34:1240–53.CrossRefPubMed
18.
Eshuis SA, Jager PL, Maguire RP, et al. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson’s disease and healthy controls. Eur J Nucl Med Mol Imaging. 2009;36:454–62.CrossRefPubMed
19.
Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson’s disease: a longitudinal 18F-dopa PET study. Neuroimage. 2011;56:1463–8.CrossRefPubMed
20.
Hirano S, Shinotoh H, Eidelberg D. Functional brain imaging of cognitive dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2012;83:963–9.CrossRefPubMed
21.
Moore RY, Whone AL, Brooks DJ. Extrastriatal monoamine neuron function in Parkinson’s disease: an 18F-dopa PET study. Neurobiol Dis. 2008;29:381–90.CrossRefPubMed
22.
Nagano-Saito A, Kato T, Arahata Y, et al. Cognitive- and motor-related regions in Parkinson’s disease: FDOPA and FDG PET studies. Neuroimage. 2004;22:553–61.CrossRefPubMed
23.
Brück A, Aalto S, Nurmi E, et al. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson’s disease. Neurobiol Aging. 2005;26:891–8.CrossRefPubMed
24.
Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–9.CrossRefPubMed
25.
Annett M. A classification of hand preference by association analysis. Br J Psychol. 1970;61:303–21.CrossRefPubMed
26.
Katz S, Downs TD, Cash HR, et al. Progress in development of the index of ADL. Gerontologist. 1970;10:20–30.CrossRefPubMed
27.
Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.CrossRefPubMed
28.
Deuschl G, Bain P, Brin M. Consensus statement of the movement disorder society on tremor. Ad hoc scientific committee. Mov Disord. 1998;13 Suppl 3:2–23.PubMed
29.
Brooks DJ, Playford ED, Ibanez V, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology. 1992;42:1554–60.CrossRefPubMed
30.
Walterfang M, van de Warrenburg BP. Cognitive impairment in "Other" movement disorders: hidden defects and valuable clues. Mov Disord. 2014;29:694–703.CrossRefPubMed
31.
Kumakura Y, Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist. 2009;15:635–50.CrossRefPubMed
32.
Ishikawa T, Dhawan V, Chaly T, et al. Clinical significance of striatal DOPA decarboxylase activity in Parkinson’s disease. J Nucl Med. 1996;37:216–22.PubMed
33.
Dhawan V, Ma Y, Pillai V, et al. Comparative analysis of striatal FDOPA uptake in Parkinson’s disease: ratio method versus graphical approach. J Nucl Med. 2002;43:1324–30.PubMed
34.
Jokinen P, Helenius H, Rauhala E, et al. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls. J Nucl Med. 2009;50:893–9.CrossRefPubMed
35.
Jaimini A, Tripathi M, D’Souza MM, et al. Utility of intrastriatal ratios of FDOPA to differentiate idiopathic Parkinson’s disease from atypical parkinsonian disorders. Nucl Med Commun. 2013;34:426–31.CrossRefPubMed
36.
Eshuis SA, Maguire RP, Leenders KL, et al. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2006;33:200–9.CrossRefPubMed
37.
Gispert JD, Pascau J, Reig S, et al. Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. Neuroimage. 2003;19:601–12.CrossRefPubMed
38.
Scherfler C, Khan NL, Pavese N, et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain. 2004;127:1332–42.CrossRefPubMed
39.
Cheesman AL, Barker RA, Lewis SJ, et al. Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2005;76:1204–10.CrossRefPubMedCentralPubMed
40.
Oishi N, Udaka F, Kameyama M, et al. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005;65:1708–15.CrossRefPubMed
41.
Eickhoff SB, Laird AR, Grefkes C, et al. Coordinate-based activation likelihood estimation meta-analysis of neuroimaging data: a random-effects approach based on empirical estimates of spatial uncertainty. Hum Brain Mapp. 2009;30:2907–26.CrossRefPubMedCentralPubMed
42.
43.
44.
Berger B, Gaspar P, Verney C. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci. 1991;14:21–7.CrossRefPubMed
45.
46.
Ellfolk U, Joutsa J, Rinne JO, et al. Striatal volume is related to phonemic verbal fluency but not to semantic or alternating verbal fluency in early Parkinson’s disease. J Neural Transm. 2014;121:33–40.CrossRefPubMedCentralPubMed
47.
Ullman MT. Is Broca’s area part of a basal ganglia thalamocortical circuit? Cortex. 2006;42:480–5.CrossRefPubMed
48.
Nobili F, Arnaldi D, Campus C, et al. Brain perfusion correlates of cognitive and nigrostriatal functions in de novo Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2011;38:2209–18.CrossRefPubMed
49.
Tomasi D, Volkow ND, Wang R, et al. Dopamine transporters in striatum correlate with deactivation in the default mode network during visuospatial attention. PLoS One. 2009;4:e6102.CrossRefPubMedCentralPubMed
50.
Manganelli F, Vitale C, Santangelo G, et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson’s disease. Brain. 2009;132:2350–5.CrossRefPubMedCentralPubMed
51.
Broussolle E, Dentresangle C, Landais P, et al. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson’s disease. J Neurol Sci. 1999;166:141–51.CrossRefPubMed
52.
Polito C, Berti V, Ramat S, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson’s disease. Neurobiol Aging. 2012;33:206.e29–39.CrossRef
53.
Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology. 2010;74:885–92.CrossRefPubMed
54.
Rakshi JS, Uema T, Ito K, et al. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson’s disease. A 3D [(18)F]dopa-PET study. Brain. 1999;122:1637–50.CrossRefPubMed
55.
Kaasinen V, Nurmi E, Brück A, et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson’s disease: sex differences in the prefrontal cortex. Brain. 2001;124:1125–30.CrossRefPubMed
56.
Brück A, Aalto S, Nurmi E, et al. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease: a two-year follow-up study. Mov Disord. 2006;21:958–63.CrossRefPubMed
Metadata
Title
Brain 18F-DOPA PET and cognition in de novo Parkinson’s disease
Authors
Agnese Picco
Silvia Morbelli
Arnoldo Piccardo
Dario Arnaldi
Nicola Girtler
Andrea Brugnolo
Irene Bossert
Lucio Marinelli
Antonio Castaldi
Fabrizio De Carli
Claudio Campus
Giovanni Abbruzzese
Flavio Nobili
Publication date
01-06-2015
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-015-3039-0

Other articles of this Issue 7/2015

European Journal of Nuclear Medicine and Molecular Imaging 7/2015 Go to the issue

Obituary

In memoriam: Ismael Mena, MD, 1928–2015

Original Article

Stress-first protocol for myocardial perfusion SPECT imaging with semiconductor cameras: high diagnostic performances with significant reduction in patient radiation doses

Original Article

Evaluation of [11C]CB184 for imaging and quantification of TSPO overexpression in a rat model of herpes encephalitis

Original Article

Relationships between myocardial perfusion abnormalities and poststress left ventricular functional impairment on cadmium-zinc-telluride imaging

Image of the Month

Correlation between 68Ga-DOTA-NOC PET/CT and 18F-FDG PET/CT in EBV-positive undifferentiated nasopharyngeal carcinoma

Letter to the Editor

Ursodeoxycholic acid versus phenobarbital pretreatment prior to hepatobiliary scintigraphy in neonatal cholestasis: is it time for shifting gears towards a practice change?